Bifogade filer
LIDDS PR 190819 New CFO
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
LIDDS has appointed Anja Peters Ohlsson as new CFO of LIDDS AB and member of the management team. Anja will succeed Bengt Norvik, who will leave his position in September following many years as CFO of the company.
Anja will assume her new role on September 2, 2019 and will report to CEO. Anja is 49 years old and holds a Major in Accounting and Finance from Uppsala University. Previous positions include CFO of Allenex/CareDx and ten years at E&Y. Anja has experience as CFO in listed companies both on Nasdaq Main Market and on Nasdaq First North.
- I am pleased to welcome Anja Peters as CFO of LIDDS. Anja has a strong financial and industrial background and will play a key role on the continued development of the company. I would also like to express my sincere gratitude to Bengt Norvik for his valuable efforts at LIDDS, says Monica Wallter, CEO of LIDDS.
In conjunction with Anja Peters assuming the role, current CFO Bengt Norvik will continue as CFO until Anja has taken office to ensure a stable and secure transition.
- I am delighted to have been appointed as new CFO for LIDDS. LIDDS is in an exciting and expansive phase, and I look forward to contributing to LIDDS development, says Anja Peters.
For additional information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 monica.wallter@liddspharma.com
This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, at 16.00 CET on August 19, 2019.
About LIDDS AB (publ)
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid® is clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com
Attachment